Cargando…

A Single Dose Versus Two Doses of Tranexamic Acid for Extracapsular Hip Fractures

Objective In this study, we aimed to compare the effectiveness of one dose of tranexamic acid (TXA) at the time of hospital admission versus two doses of TXA (one at the time of hospital admission and another dose intraoperatively) in reducing perioperative total blood loss in patients with extracap...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiganti, Max, Pipitone, Olivia, Than, Justin, Stanley, Richard, Passanise, Angela, Krumrey, Jacqueline
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8841038/
https://www.ncbi.nlm.nih.gov/pubmed/35174034
http://dx.doi.org/10.7759/cureus.21239
_version_ 1784650750053318656
author Jiganti, Max
Pipitone, Olivia
Than, Justin
Stanley, Richard
Passanise, Angela
Krumrey, Jacqueline
author_facet Jiganti, Max
Pipitone, Olivia
Than, Justin
Stanley, Richard
Passanise, Angela
Krumrey, Jacqueline
author_sort Jiganti, Max
collection PubMed
description Objective In this study, we aimed to compare the effectiveness of one dose of tranexamic acid (TXA) at the time of hospital admission versus two doses of TXA (one at the time of hospital admission and another dose intraoperatively) in reducing perioperative total blood loss in patients with extracapsular hip fractures. Methods This retrospective cohort study included 80 patients from a single institution who underwent surgical fixation for extracapsular hip fractures. Forty patients received a single dose of 1 gram of TXA at the time of hospital admission (per standardized protocol of an ongoing research study at the time), and 40 patients received the same dose of TXA on hospital admission as well as a second dose of 1 gram of TXA intraoperatively at the time of incision (per standard practice change following the completion of the research study). The primary study outcome of interest was total blood loss, which was calculated by estimating blood volume via Nadler’s formula followed by calculating the total blood loss with the hemoglobin dilution method. Secondary outcomes included blood transfusion rates, hospital length of stay (LOS), and 30-day mortality. Results Patient gender, age, the American Society of Anesthesiologists (ASA) score, procedure length, fracture type, hardware type, and hemoglobin on hospital arrival were similar across the study groups (all p>0.05), though the twice-dosed group had a higher average BMI (26.4 kg/m(2) vs. 24 kg/m(2), p=0.04). When adjusting for BMI, the twice-dosed group was estimated to have a slightly larger but non-significant difference in total blood loss (115-ml difference, 95% CI: 158.2-389.3, p=0.40) compared to the single-dose TXA group. More patients in the twice-dosed group required blood transfusion compared to the single-dose TXA group, though this was not statistically significant (30.0% vs. 17.5%, adjusted OR=1.64, 95% CI: 0.55-5.12, p=0.38). The distribution of hospital LOS and 30-day mortality rates were similar across the groups (p=0.13 and p>0.99). Conclusion In the setting of surgically treated extracapsular hip fractures, patients who received one dose of TXA at the time of hospital admission and a second intraoperative dose of TXA did not demonstrate significant differences in total blood loss or a need for blood transfusion compared to patients who only received a single dose of TXA at the time of hospital admission.
format Online
Article
Text
id pubmed-8841038
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-88410382022-02-15 A Single Dose Versus Two Doses of Tranexamic Acid for Extracapsular Hip Fractures Jiganti, Max Pipitone, Olivia Than, Justin Stanley, Richard Passanise, Angela Krumrey, Jacqueline Cureus Orthopedics Objective In this study, we aimed to compare the effectiveness of one dose of tranexamic acid (TXA) at the time of hospital admission versus two doses of TXA (one at the time of hospital admission and another dose intraoperatively) in reducing perioperative total blood loss in patients with extracapsular hip fractures. Methods This retrospective cohort study included 80 patients from a single institution who underwent surgical fixation for extracapsular hip fractures. Forty patients received a single dose of 1 gram of TXA at the time of hospital admission (per standardized protocol of an ongoing research study at the time), and 40 patients received the same dose of TXA on hospital admission as well as a second dose of 1 gram of TXA intraoperatively at the time of incision (per standard practice change following the completion of the research study). The primary study outcome of interest was total blood loss, which was calculated by estimating blood volume via Nadler’s formula followed by calculating the total blood loss with the hemoglobin dilution method. Secondary outcomes included blood transfusion rates, hospital length of stay (LOS), and 30-day mortality. Results Patient gender, age, the American Society of Anesthesiologists (ASA) score, procedure length, fracture type, hardware type, and hemoglobin on hospital arrival were similar across the study groups (all p>0.05), though the twice-dosed group had a higher average BMI (26.4 kg/m(2) vs. 24 kg/m(2), p=0.04). When adjusting for BMI, the twice-dosed group was estimated to have a slightly larger but non-significant difference in total blood loss (115-ml difference, 95% CI: 158.2-389.3, p=0.40) compared to the single-dose TXA group. More patients in the twice-dosed group required blood transfusion compared to the single-dose TXA group, though this was not statistically significant (30.0% vs. 17.5%, adjusted OR=1.64, 95% CI: 0.55-5.12, p=0.38). The distribution of hospital LOS and 30-day mortality rates were similar across the groups (p=0.13 and p>0.99). Conclusion In the setting of surgically treated extracapsular hip fractures, patients who received one dose of TXA at the time of hospital admission and a second intraoperative dose of TXA did not demonstrate significant differences in total blood loss or a need for blood transfusion compared to patients who only received a single dose of TXA at the time of hospital admission. Cureus 2022-01-14 /pmc/articles/PMC8841038/ /pubmed/35174034 http://dx.doi.org/10.7759/cureus.21239 Text en Copyright © 2022, Jiganti et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Orthopedics
Jiganti, Max
Pipitone, Olivia
Than, Justin
Stanley, Richard
Passanise, Angela
Krumrey, Jacqueline
A Single Dose Versus Two Doses of Tranexamic Acid for Extracapsular Hip Fractures
title A Single Dose Versus Two Doses of Tranexamic Acid for Extracapsular Hip Fractures
title_full A Single Dose Versus Two Doses of Tranexamic Acid for Extracapsular Hip Fractures
title_fullStr A Single Dose Versus Two Doses of Tranexamic Acid for Extracapsular Hip Fractures
title_full_unstemmed A Single Dose Versus Two Doses of Tranexamic Acid for Extracapsular Hip Fractures
title_short A Single Dose Versus Two Doses of Tranexamic Acid for Extracapsular Hip Fractures
title_sort single dose versus two doses of tranexamic acid for extracapsular hip fractures
topic Orthopedics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8841038/
https://www.ncbi.nlm.nih.gov/pubmed/35174034
http://dx.doi.org/10.7759/cureus.21239
work_keys_str_mv AT jigantimax asingledoseversustwodosesoftranexamicacidforextracapsularhipfractures
AT pipitoneolivia asingledoseversustwodosesoftranexamicacidforextracapsularhipfractures
AT thanjustin asingledoseversustwodosesoftranexamicacidforextracapsularhipfractures
AT stanleyrichard asingledoseversustwodosesoftranexamicacidforextracapsularhipfractures
AT passaniseangela asingledoseversustwodosesoftranexamicacidforextracapsularhipfractures
AT krumreyjacqueline asingledoseversustwodosesoftranexamicacidforextracapsularhipfractures
AT jigantimax singledoseversustwodosesoftranexamicacidforextracapsularhipfractures
AT pipitoneolivia singledoseversustwodosesoftranexamicacidforextracapsularhipfractures
AT thanjustin singledoseversustwodosesoftranexamicacidforextracapsularhipfractures
AT stanleyrichard singledoseversustwodosesoftranexamicacidforextracapsularhipfractures
AT passaniseangela singledoseversustwodosesoftranexamicacidforextracapsularhipfractures
AT krumreyjacqueline singledoseversustwodosesoftranexamicacidforextracapsularhipfractures